Gadopentetate dimeglumine (gadolinium diethylenetriaminepentaacetic acid [DTPA] ) was prospectively administered to 15 consecutive neonates and young infants (less than 6 weeks old) referred for routine cranial magnetic resonance (MR) imaging. The goals of the study were (a) to provide preliminary safety and efficacy data concerning the use of this drug in neonates and (b) to determine whether the patterns and time course of normal contrast material enhancement were similar to those seen in older children and adults. Gd-DTPA-enhanced MR images revealed significant abnormalities not seen on the MR images obtained before administration of contrast material in four (27%) of es, infundibulum, choroid plexus, dura, major dural sinuses, nasopharyngeal mucosa, and smaller cortical veins (Fig 1) . In two premature infants, enhanced subependymal veins along the margins of the lateral ventricles were noted to be slightly more prominent than is normally seen in adults, which may relate to the relatively larger size of these vessels and greater vascularity of the ependymal and subependymal regions in the premature infant (19, 20) .
Enhancing lesions were encountered in five (33%) of 15 patients (Table 1). In four of these patients, contrast enhancement significantly modified the diagnosis made before administration of contrast-material ( Figs 2,3) ; in the fifth patient, contrast enhancement was incidentally noted at the margin of a cephalhematoma (Fig 4) .
The images of two infants obtained 4 hours after injection demonstrated marked persistent contrast enhancement in normal structures (Fig 5) . Serial measurements revealed an approximately 50% decrease in the level of contrast enhancement during this 4-hour period for most structures (Fig  6) . Even with this absolute reduction in enhancement signal intensity, however, vivid contrast enhancement of many normal structures was still visually striking.
DISCUSSION
The pharmacokinetics of intravenously administered Gd-DTPA have been well studied in adults (21) (22) (23) On injection, the meglumine salt completely dissociates from the gadopentetate complex. No detectable biotransformation or decomposition occurs. The gadopentetate complex rapidly diffuses into the extracellular compartment of the body, with a volume of distribution almost identical to the extracellular fluid volume (ECV). Gd-DTPA is exclusively eliminated in the urine and has a clearance rate similar to that of substances that are subject to glomerular filtration alone.
In adult volunteers, the pharmacokinetics of intravenously administered Gd-DTPA conforms closely to a classic two-compartment open model, with a mean elimination half-life of approximately 1.5 hours (21) . To our knowledge, however, no corresponding pharmacokinetic study of Gd-DTPA has been performed in infants or children. Nevertheless, it is relatively easy to make reasonable estimates of the half-life of Gd-DTPA injected into neonates. These estimates are based on three broad assumptions that have been shown to be true in adults: (a) that the diffusion time of Gd-DTPA from blood to the ECV is small compared with its elimination half-life, (b) that the volume of distribution of Gd-DTPA approximates the extracellular fluid space, and (c) that Gd-DTPA is totally cleared by glomerular filtration.
For substances that fit these assumptions (eg, Gd-DTPA or inulin), the elimination half-life (TV/2) can easily be calculated as follows (24, 25) (Table 2) . As shown in Table 2, the expected half-life of Gd-DTPA is greater than 6 hours in the full-term newborn and may be significantly higher in the premature infant. By age 6-8 weeks, however, the mean elimination half-life approaches the adult value of 1.5 hours. This marked age dependency of the half-life of Gd-DTPA results from differences in the relative volumes of distribution and GFRs between neonates and adults. The quantity and distribution of body water change markedly throughout fetal development and infancy (24, 26, 29, 30) . In the 3rd fetal month, total-body water represents about 94% of the body weight (29) .
As gestation progresses, the amount of total-body water per kilogram declines, reaching approximately 78% of body weight by term. Characteristic changes also occur in the partition of body water between the intracellular and extracellular spaces. The ECV decreases from 60% of body weight during the 5th fetal month to about 45% at term. After birth, the amount of totalbody water per kilogram continues to decrease, due at least in part to a contraction of the ECV (29, 30 fants until further data are available. The second important difference between infants and adults concerning contrast material concerns the maturation of renal function. GFR is approximately 0.5 mL/min in premature infants of less than 34 weeks gestation, while term newborns have a GFR of about 2.5 mL/min (26, 31, 32) . There is a sharp postnatal increase in GFR, which doubles by 2 weeks of age (27, 28) . When corrected for body surface area, GFR reaches adult values by approximately 1-2 years of age. Hemodynamic and morphologic changes seem to be responsible for this rapid maturation of renal function: a decrease in renal vascular resistance, an increase in effective filtration pressure, and an increase in glomerular permeability and filtering area (26) . Renal tubular function also is immature in the neonate, resulting in a limited renal concentrating ability. This effect limits the visualization of the renal collecting system on excretory urograms obtained during the first few weeks of life. Because Gd-DTPA is apparently eliminated totally by glomerular filtration, however, tubular maturity does not play a role in its prolonged half-life.
Knowledge of the prolonged halflife of Gd-DTPA in neonates and young infants may be useful in certain clinical circumstances. For example, a sedated infant who awakes during Gd-DTPA infusion may be removed from the imager, resedated, and reimaged within 1-2 hours with no need for injection of additional contrast material. Alternatively, if only a postcontrast study is desired, the infant may be sedated and undergo Gd-DTPA infusion while still in the neonatal care unit, followed by nonurgent MR imaging.
Our preliminary analysis concerning the half-life of Gd-DTPA in neonates contains several unproved assumptions that await further experimental verification. It is not known whether the diffusion time of Gd-DTPA from blood to the extracellular space is the same in neonates and adults. We do not know whether other significant modes of Gd-DTPA excretion exist in neonates, such as into the gastrointestinal tract or biliary system. To our knowledge, no pharmacokinetic studies exist of Gd-DTPA in human infants or immature animals. Nevertheless, it is clear that the half-life of Gd-DTPA is signifi-228 * Radiology 
